The genetic testing firm 23andMe said on Monday it would cut about 40%, or 200 employees, from its workforce and discontinue further development of all its therapies as part of a restructuring program.
“We are taking these difficult but necessary actions as we restructure 23andMe and focus on the long-term success of our core consumer business and research partnerships,” said the company’s CEO, Anne Wojcicki.
